Press Releases

and/or
567 News Releases found
Richard J. O’Reilly
Media Advisory
Transplantation Shown to Be Highly Effective in Treating Immune Deficiency in Children

Babies who are born with severe combined immunodeficiency can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard O’Reilly.
Media Advisory
Memorial Sloan Kettering Ranks First in the Nation for Cancer Care

Memorial Sloan Kettering Cancer Center is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals.
Memorial Sloan Kettering Appoints DigitasLBi as Digital Agency of Record Phase2 Selected as Drupal Technology Partner

Memorial Sloan Kettering Cancer Center (MSK) is partnering with DigitasLBi and Phase2 to help expand MSK's digital reach.
Craig Thompson
Memorial Sloan Kettering Cancer Center and Quest Diagnostics Partner to Advance Precision Medicine in Cancer Diagnosis and Treatment

Memorial Sloan Kettering and Quest Diagnostics announced a joint collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors.
Pictured: Marie-Josée and Henry R. Kravis
Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology

Memorial Sloan Kettering launched the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, an ambitious initiative to improve cancer care and research through genomic analysis.
Pictured: Mark Kris
Study Using Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients with Targeted Therapies Transforms Care

New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Pictured: William Tap
Phase I Data Suggest PLX3397 Is a Potential Therapy for Patients with Advanced Pigmented Villonodular Synovitis

New research from Memorial Sloan Kettering highlighted in advance of the 50th Annual Meeting of the American Society of Clinical Oncology demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of advanced pigmented villonodular synovitis, a rare and debilitating joint disease.
Paying It Forward: Breakthrough Prize Winners and Institutions Commit $3 Million in Support of Next Generation of Scientists

Three winners of the first-ever Breakthrough Prizes — Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center; Cornelia I. Bargmann, PhD, of the Rockefeller University; and Lewis C. Cantley, PhD, of Weill Cornell Medical College — have committed a portion of their Breakthrough Prize in Life Sciences award to establish a new annual prize for promising postdoctoral trainees.
Memorial Sloan Kettering Establishes New Center for Molecular Imaging and Nanotechnology

Memorial Sloan Kettering has launched a collaborative translational research center that will unite researchers specializing in two rapidly growing fields: molecular imaging and nanotechnology.
cancer cell
Study Reveals Mechanisms Cancer Cells Use to Establish Metastatic Brain Tumors

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.